Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Telaprevir

FDA-approved product (tablet, oral), marketed as Incivek.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Telaprevir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Antivirals for treatment of hcv infections
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP02

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis46.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Telaprevir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Telaprevir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)

    NCT01513941 · start 2012-04

    Registered record
    Registry ID
    NCT01513941
    Conditions
    Chronic Hepatitis C
    Interventions
    Telaprevir; Ribavirin; Pegylated-Interferon-alfa-2a
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-04
    Completion
    2014-06
    Enrolment
    163

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionTelaprevir; Ribavirin; Pegylated-Interferon-alfa-2a
    PhasePhase 3
    Registry statusCompleted

  • Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir

    NCT01582035 · start 2012-04

    Registered record
    Registry ID
    NCT01582035
    Conditions
    Hepatitis C
    Interventions
    TMC647055; TMC647055; TVR; TVR; TVR; PegFN; RBV
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-04
    Completion
    2013-11
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionTMC647055; TMC647055; TVR; TVR +3 more
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).

    NCT01563328 · start 2012-03-01

    Registered record
    Registry ID
    NCT01563328
    Conditions
    Infection, Human Immunodeficiency Virus
    Interventions
    DTG; BCV; TVR
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-03-01
    Completion
    2012-05-01
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus
    InterventionDTG; BCV; TVR
    PhasePhase 1
    Registry statusCompleted

  • An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

    NCT01467505 · start 2012-02

    Registered record
    Registry ID
    NCT01467505
    Conditions
    Hepatitis C
    Interventions
    Telaprevir; Ribavirin; Pegylated Interferon Alfa-2a; Immunosuppressant Regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2012-02
    Completion
    2014-04
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionTelaprevir; Ribavirin; Pegylated Interferon Alfa-2a; Immunosuppressant Regimen
    PhasePhase 2
    Registry statusTerminated

  • TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy

    NCT01485991 · start 2012-02

    Registered record
    Registry ID
    NCT01485991
    Conditions
    Hepatitis C
    Interventions
    TMC435; TVR
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-02
    Completion
    2014-04
    Enrolment
    771

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionTMC435; TVR
    PhasePhase 3
    Registry statusCompleted

  • Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C

    NCT01467492 · start 2012-01

    Registered record
    Registry ID
    NCT01467492
    Conditions
    Hepatitis C
    Interventions
    Telaprevir; Ribavirin; Pegylated Interferon Alfa-2a
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2012-01
    Completion
    2014-05
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionTelaprevir; Ribavirin; Pegylated Interferon Alfa-2a
    PhasePhase 4
    Registry statusTerminated

  • Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection

    NCT01492426 · start 2012-01

    Registered record
    Registry ID
    NCT01492426
    Conditions
    Hepatitis C
    Interventions
    Daclatasvir; Telaprevir; Peginterferon alfa-2a; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-01
    Completion
    2014-03
    Enrolment
    605

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionDaclatasvir; Telaprevir; Peginterferon alfa-2a; Ribavirin
    PhasePhase 3
    Registry statusCompleted

  • A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

    NCT01467479 · start 2011-12

    Registered record
    Registry ID
    NCT01467479
    Conditions
    Hepatitis C
    Interventions
    Telaprevir; Ribavirin; Pegylated Interferon Alfa-2a; Highly Active Antiretroviral Therapy (HAART)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2011-12
    Completion
    2014-02
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionTelaprevir; Ribavirin; Pegylated Interferon Alfa-2a; Highly Active Antiretroviral Therapy (HAART)
    PhasePhase 3
    Registry statusTerminated

  • Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

    NCT01355289 · start 2011-11

    Registered record
    Registry ID
    NCT01355289
    Conditions
    Thrombocytopenia
    Interventions
    Avatrombopag; Placebo; Pegylated interferon (PEG-IFN); Telaprevir; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-11
    Completion
    2014-05
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombocytopenia
    InterventionAvatrombopag; Placebo; Pegylated interferon (PEG-IFN); Telaprevir +1 more
    PhasePhase 2
    Registry statusCompleted

  • Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype

    NCT01459913 · start 2011-11

    Registered record
    Registry ID
    NCT01459913
    Conditions
    Hepatitis C, Chronic
    Interventions
    Telaprevir; Pegylated Interferon Alfa-2a; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2011-11
    Completion
    2014-01
    Enrolment
    239

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionTelaprevir; Pegylated Interferon Alfa-2a; Ribavirin
    PhasePhase 3
    Registry statusTerminated

  • Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

    NCT01359644 · start 2011-06

    Registered record
    Registry ID
    NCT01359644
    Conditions
    Chronic Hepatitis C
    Interventions
    PSI-7977; Daclatasvir; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-06
    Completion
    2013-10
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionPSI-7977; Daclatasvir; Ribavirin
    PhasePhase 2
    Registry statusCompleted

  • Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen

    NCT01332955 · start 2011-04

    Registered record
    Registry ID
    NCT01332955
    Conditions
    Hepatitis C, Chronic; HIV Infection
    Interventions
    Telaprevir; pegIFN alfa-2a; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-04
    Completion
    2013-09
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic; HIV Infection
    InterventionTelaprevir; pegIFN alfa-2a; Ribavirin
    PhasePhase 2
    Registry statusCompleted

  • French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin

    NCT01514890 · start 2011-02

    Registered record
    Registry ID
    NCT01514890
    Conditions
    Chronic Hepatitis C
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-02
    Completion
    2014-03
    Enrolment
    675

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Drug-Drug Interaction Study Between Telaprevir and Buprenorphine

    NCT01275599 · start 2011-01

    Registered record
    Registry ID
    NCT01275599
    Conditions
    Hepatitis C; Opioid-Related Disorders
    Interventions
    telaprevir; buprenorphine/naloxone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-01
    Completion
    Not recorded
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Opioid-Related Disorders
    Interventiontelaprevir; buprenorphine/naloxone
    PhasePhase 1
    Registry statusCompleted

  • VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

    NCT01241760 · start 2010-12

    Registered record
    Registry ID
    NCT01241760
    Conditions
    Genotype 1 Chronic Hepatitis C; Treatment Naive
    Interventions
    Ribavirin; Telaprevir; Pegylated interferon alfa-2a; Telaprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-12
    Completion
    2012-11
    Enrolment
    744

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGenotype 1 Chronic Hepatitis C; Treatment Naive
    InterventionRibavirin; Telaprevir; Pegylated interferon alfa-2a; Telaprevir
    PhasePhase 3
    Registry statusCompleted